Clinical effect of rituximab as early administration for refractory thrombotic thrombocytopenic purpura associated with connective tissue diseases

Abstract As previous reports regarding rituximab usage for refractory thrombotic thrombocytopenic purpura (TTP) patients with connective tissue diseases (CTD) are limited, it is essential to clarify the clinical effect of early rituximab administration for refractory TTP with CTD in clinical practice. We retrospectively analysed three refractory TTP patients with CTD (plasma exchange [PE]-refractory case (case 2) or cases (case 1 and case 3) with high titers of von Willebrand factor-cleaving protease [ADAMTS13] inhibitor) in a single institution during 2012–2015. The patients were treated with PE/plasma infusion, steroids, and off-label use of rituximab treatment as early administration, at a dosage of 375 mg/m2 weekly with four or eight repeats. Owing to the early diagnosis of refractory TTP with ADAMTS13 activity-deficiency and presence of ADAMTS13 inhibitors (case 1: 2.5, case 2: 1.0, case 3: 6.6), and the subsequent early rituximab treatment combined with PE (case 1: day 1, case 2: day 12, case 3: day 1), all three patients achieved early complete remission and survived without relapse to 779, 498 and 388 days, respectively. In all three cases, the recovery of platelet counts (>50 × 109/L) was achieved within three weeks of rituximab administration. The adverse effect (only an infusion reaction) was safe and tolerable. In contrast to previous reports regarding rituximab treatment for TTP in CTD patients, in our case series study, it’s to the credit that we described the detailed clinical course and short- and long-term effect of early rituximab administration at refractory TTP patients with CTD in clinical practice.

[1]  J. Ultmann,et al.  THROMBOTIC THROMBOCYTOPENIC PURPURA: REPORT OF 16 CASES AND REVIEW OF THE LITERATURE , 1966 .

[2]  Mitsuru Murata,et al.  Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy , 2016, International Journal of Hematology.

[3]  S. Gitlow,et al.  GENERALIZED CAPILLARY AND ARTERIOLAR THROMBOSIS: REPORT OF TWO CASES WITH A DISCUSSION OF THE LITERATURE , 1939 .

[4]  K. Nitta,et al.  Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. , 2010, Internal medicine.

[5]  K. Titani,et al.  Upshaw-Schulman Syndrome Revisited: A Concept of Congenital Thrombotic Thrombocytopenic Purpura , 2001, International journal of hematology.

[6]  B. Hunt,et al.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias , 2003, British journal of haematology.

[7]  D. Harvey,et al.  Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients , 2008, Journal of hematology & oncology.

[8]  Ami A. Shah,et al.  Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties , 2007, Nature Clinical Practice Rheumatology.

[9]  J. Moake,et al.  Recent advances in thrombotic thrombocytopenic purpura. , 2004, Hematology. American Society of Hematology. Education Program.

[10]  J. Thumboo,et al.  A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. , 2009, Rheumatology.

[11]  M. Scully,et al.  Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura , 2010, Journal of thrombosis and haemostasis : JTH.

[12]  K. Tsubota,et al.  Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity , 2004, Modern rheumatology.

[13]  K. Fujikawa,et al.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. , 2001, Blood.

[14]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[15]  T. Matsuyama,et al.  Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activity , 2006, Transfusion.

[16]  W. Miesbach,et al.  The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine , 2005, British journal of haematology.

[17]  J. Kelton,et al.  Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura , 1992 .

[18]  H. Wada,et al.  The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. , 2004, Seminars in hematology.

[19]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[20]  E. Gabazza,et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF‐cleaving protease activity , 2002, Transfusion.

[21]  E. Moschcowitz.  Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease , 1924 .

[22]  T. Ishida,et al.  Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment , 2007, Clinical Rheumatology.

[23]  K. Fujikawa,et al.  Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura* , 2001, The Journal of Biological Chemistry.

[24]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[25]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.

[26]  L. Goodnough,et al.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. , 2004, Blood.

[27]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[28]  M. Matsumoto,et al.  Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan , 2012, PloS one.

[29]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[30]  P. Aridon,et al.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome. , 2010, Blood transfusion = Trasfusione del sangue.

[31]  Ji Won Kim,et al.  Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: the 10‐year experience of a single center , 2011, Hematology.

[32]  Y. Miwa,et al.  Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital. , 2006, Clinical and experimental rheumatology.

[33]  M. Matsumoto,et al.  Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011. , 2013, Internal medicine.

[34]  M. Radhi,et al.  Thrombotic Microangiopathies , 2012, ISRN hematology.

[35]  M. Matsumoto,et al.  Rituximab Provided Long-Term Remission in a Patient with Refractory Relapsing Thrombotic Thrombocytopenic Purpura , 2005, International journal of hematology.

[36]  D. Sène,et al.  Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. , 2008, Lupus.

[37]  M. Matsumoto,et al.  Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. , 2010, Internal medicine.

[38]  Doyeun Oh,et al.  Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience , 2011, International journal of hematology.

[39]  松山 友美.  Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases , 2009 .

[40]  F. Peyvandi,et al.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies , 2012, British journal of haematology.

[41]  B. Lämmle,et al.  Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. , 1998, Blood.

[42]  G. Choukroun,et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.

[43]  T. Fukuda,et al.  Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus , 2010, Modern rheumatology.

[44]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[45]  T. Niewold,et al.  Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. , 2006, The Journal of rheumatology.